James J. Dignam to Chemotherapy, Adjuvant
This is a "connection" page, showing publications James J. Dignam has written about Chemotherapy, Adjuvant.
Connection Strength
0.546
-
Efficacy of systemic adjuvant therapy for breast cancer in African-American and Caucasian women. J Natl Cancer Inst Monogr. 2001; (30):36-43.
Score: 0.172
-
Hazard of recurrence and adjuvant treatment effects over time in lymph node-negative breast cancer. Breast Cancer Res Treat. 2009 Aug; 116(3):595-602.
Score: 0.074
-
Body mass index and outcomes in patients who receive adjuvant chemotherapy for colon cancer. J Natl Cancer Inst. 2006 Nov 15; 98(22):1647-54.
Score: 0.065
-
Findings from recent National Surgical Adjuvant Breast and Bowel Project adjuvant studies in stage I breast cancer. J Natl Cancer Inst Monogr. 2001; (30):62-6.
Score: 0.043
-
Occurrence of stroke with tamoxifen in NSABP B-24. Lancet. 2000 Mar 04; 355(9206):848-9.
Score: 0.041
-
Coronary heart disease mortality and adjuvant tamoxifen therapy. J Natl Cancer Inst. 1997 Jun 04; 89(11):776-82.
Score: 0.034
-
Outcomes among black patients with stage II and III colon cancer receiving chemotherapy: an analysis of ACCENT adjuvant trials. J Natl Cancer Inst. 2011 Oct 19; 103(20):1498-506.
Score: 0.023
-
Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS. J Natl Cancer Inst. 2011 Mar 16; 103(6):478-88.
Score: 0.022
-
Population-based survival-cure analysis of ER-negative breast cancer. Breast Cancer Res Treat. 2010 Aug; 123(1):257-64.
Score: 0.020
-
Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in patients treated by breast-conserving therapy in five National Surgical Adjuvant Breast and Bowel Project protocols of node-negative breast cancer. J Clin Oncol. 2009 May 20; 27(15):2466-73.
Score: 0.019
-
Prognosis and treatment of patients with breast tumors of one centimeter or less and negative axillary lymph nodes. J Natl Cancer Inst. 2001 Jan 17; 93(2):112-20.
Score: 0.011
-
Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer. J Natl Cancer Inst. 1997 Nov 19; 89(22):1673-82.
Score: 0.009
-
Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst. 1996 Nov 06; 88(21):1529-42.
Score: 0.008
-
Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor-negative tumors: eight-year results from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-13 and first report of findings from NSABP B-19 comparing methotrexate and fluorouracil with conventional cyclophosphamide, methotrexate, and fluorouracil. J Clin Oncol. 1996 Jul; 14(7):1982-92.
Score: 0.008